PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 10752935

A comparison of the pattern- and total deviation-based Glaucoma Change Probability programs.

J Katz
View original source ↗Export metadata ↓

Abstract

PURPOSE: To compare the rates of progression of visual field defects in glaucoma patients, by using the Glaucoma Change Probability program based on pattern deviation and total deviation probability maps. METHODS: The incidence of progression of visual field loss among 67 eyes of 56 glaucoma patients with an average of 6 years of follow-up was estimated by applying the criteria set by the Early Manifest Glaucoma Treatment study, which uses the output from the Glaucoma Change Probability (GCP) program of the Humphrey Field Analyzer (San Leandro, CA) based on pattern deviation probability maps. This incidence estimate was compared with one obtained by applying the same criteria but using the GCP program based on total deviation probability maps. RESULTS: The 6-year incidence of progression among patients with glaucoma was 23.2% and 35.7% using the GCP program based on pattern deviation and total deviation probability maps, respectively. Not all patients in whom visual field loss progressed according to pattern deviation also showed progression according to total deviation. CONCLUSIONS: The GCP program based on pattern deviation probability maps appears to screen out patients in whom progression of visual field defects may be due to diffuse loss from cataract, but the pattern deviation maps may also be identifying other types of field loss not detected by the total deviation maps.

Explore related subjects

Disease ProgressionFollow-Up StudiesGlaucomaHumansMiddle AgedProbabilityVision DisordersVisual Field TestsVisual FieldsComparative StudyJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Katz. 2000. A comparison of the pattern- and total deviation-based Glaucoma Change Probability programs.. https://pubmed.ncbi.nlm.nih.gov/10752935/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Complex partial status epilepticus associated with anti-Hu paraneoplastic syndrome.

Although seizures can be a manifestation of paraneoplastic disorders, there are few descriptions of the association between the anti-Hu paraneoplastic syndrome and epilepsia partialis continua. A new case of refractory complex partial status epilepticus in a patient with a paraneoplastic syndrome associated with a poorly differentiated mediastinal tumor that expressed Hu antigen is described clinically, pathologically, and electrographically. We discuss the presentation of focal seizures in a disease that is characterized by diffuse pathologic involvement of the brain. The progression of EEG, MRI, and clinical findings during the course of the illness is also discussed. To our knowledge, this is the first description of paraneoplastic epilepsia partialis continua associated with diffuse pathologic abnormalities.

Disease Progression↗
PubMed2003

Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection.

The natural outcome and response to treatment in hepatitis C virus (HCV) infection varies between individuals. Whereas some variation may be attributable to viral and environmental variables, it is probable that host genetic background also plays a significant role. Interleukin (IL)-10 has a key function in the regulation of cellular immune responses and in the suppression of pro-inflammatory cytokine secretion. Functional polymorphisms in the IL-10 gene have been described. We investigated the role of these polymorphisms in the outcome of HCV infection, treatment response and development of fibrosis in a case-control association study. Self-limiting infection was associated with the IL-10 (-592) AA genotype (OR=2.05; P=0.028). Persistent infection was associated with the IL-10 (-1082) GG genotype (OR=0.48; P=0.018). Sustained response to interferon therapy was associated with the IL-10 (-1082) GG genotype (OR=2.28; P=0.005) and the haplotype GCC (OR=2.27; P=0.020). The IL-10 (-1082) AA genotype and the ATA/ATA and ACC/ACC homozygous haplotypes were more frequent among patients with rapid fibrosis. Furthermore, the microsatellites IL-10.R and IL-10.G were associated with interferon response with IL-10R.2 conveying susceptibility (OR=1.80; P=0.034), and IL-10R.3 and IL-10.G13 being protective (OR=0.47; P=0.003 and OR=0.59; P=0.042, respectively). We conclude that polymorphisms in the IL-10 promoter appear to have some influence on the outcome of HCV infection, treatment and development of fibrosis.

Disease Progression↗